Cargando…

Synthesis of chiral sulfinate esters by asymmetric condensation

Achiral sulfur functional groups, such as sulfonamide, sulfone, thiol and thioether, are common in drugs and natural products. By contrast, chiral sulfur functional groups are often neglected as pharmacophores(1–3), although sulfoximine, with its unique physicochemical and pharmacokinetic properties...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Ang, Esther Cai Xia, Yang, Ziqi, Kee, Choon Wee, Tan, Choon-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985065/
https://www.ncbi.nlm.nih.gov/pubmed/35158370
http://dx.doi.org/10.1038/s41586-022-04524-4
Descripción
Sumario:Achiral sulfur functional groups, such as sulfonamide, sulfone, thiol and thioether, are common in drugs and natural products. By contrast, chiral sulfur functional groups are often neglected as pharmacophores(1–3), although sulfoximine, with its unique physicochemical and pharmacokinetic properties(4,5), has been recently incorporated into several clinical candidates. Thus, other sulfur stereogenic centres, such as sulfinate ester, sulfinamide, sulfonimidate ester and sulfonimidamide, have started to attract attention. The diversity and complexity of these sulfur stereogenic centres have the potential to expand the chemical space for drug discovery(6–10). However, the installation of these structures enantioselectively into drug molecules is highly challenging. Here we report straightforward access to enantioenriched sulfinate esters via asymmetric condensation of prochiral sulfinates and alcohols using pentanidium as an organocatalyst. We successfully coupled a wide range of sulfinates and bioactive alcohols stereoselectively. The initial sulfinates can be prepared from existing sulfone and sulfonamide drugs, and the resulting sulfinate esters are versatile for transformations to diverse chiral sulfur pharmacophores. Through late-stage diversification(11,12) of celecoxib and other drug derivatives, we demonstrate the viability of this unified approach towards sulfur stereogenic centres.